Anebulo Pharmaceuticals (ANEB) News Today $2.20 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 22, 2024 | businesswire.comAnebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic EffectsJuly 16, 2024 | americanbankingnews.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Growth in Short InterestJuly 15, 2024 | marketbeat.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest UpdateAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 12,500 shares, a growth of 13.6% from the June 15th total of 11,000 shares. Based on an average daily volume of 7,200 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.1% of the shares of the company are short sold.May 15, 2024 | investorplace.comANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024May 15, 2024 | finance.yahoo.comAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent UpdatesMay 15, 2024 | businesswire.comGalehead Development to Collaborate With Rivian Automotive on Renewable Energy Project DevelopmentMay 14, 2024 | marketbeat.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Drop in Short InterestAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) saw a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 17,900 shares, a decrease of 10.9% from the April 15th total of 20,100 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily volume of 5,600 shares, the days-to-cover ratio is currently 3.2 days.April 30, 2024 | marketbeat.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Increase in Short InterestAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 20,100 shares, an increase of 6.9% from the March 31st total of 18,800 shares. Based on an average trading volume of 5,600 shares, the days-to-cover ratio is currently 3.6 days. Currently, 0.2% of the shares of the stock are sold short.April 17, 2024 | morningstar.comAnebulo Pharmaceuticals Inc 214April 10, 2024 | marketbeat.comShort Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Rises By 308.7%Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 18,800 shares, an increase of 308.7% from the March 15th total of 4,600 shares. Based on an average trading volume of 5,600 shares, the short-interest ratio is currently 3.4 days. Approximately 0.2% of the company's shares are short sold.April 2, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Abivax SA Sponsored ADR (ABVX)March 18, 2024 | marketbeat.comShort Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Expands By 10.0%Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 29th, there was short interest totalling 3,300 shares, an increase of 10.0% from the February 14th total of 3,000 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 9,000 shares, the days-to-cover ratio is presently 0.4 days.February 26, 2024 | msn.comMilestone rallies 23% on FDA update for tachycardia drugFebruary 16, 2024 | markets.businessinsider.comAnebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA TrackFebruary 15, 2024 | msn.comNew Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What’s the Latest?February 14, 2024 | msn.comSubstance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication DrugFebruary 14, 2024 | marketbeat.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Large Decline in Short InterestAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,700 shares, a decrease of 18.2% from the January 15th total of 3,300 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 14,400 shares, the short-interest ratio is currently 0.2 days.February 13, 2024 | finance.yahoo.comAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesFebruary 7, 2024 | marketbeat.comAnebulo Pharmaceuticals (ANEB) to Release Quarterly Earnings on ThursdayAnebulo Pharmaceuticals (NASDAQ:ANEB) will be releasing earnings on Thursday, February 8, Yahoo Finance reports.January 20, 2024 | benzinga.comAnebulo Pharmaceuticals Stock (NASDAQ:ANEB) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comAnebulo Pharmaceuticals, Inc. (ANEB)December 17, 2023 | nasdaq.comAnebulo Pharmaceuticals (FRA:214) Price Target Increased by 21.00% to 6.80December 9, 2023 | morningstar.comAnebulo Pharmaceuticals Inc ANEBNovember 21, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Brainsway (BWAY)November 17, 2023 | markets.businessinsider.comBuy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication TreatmentNovember 15, 2023 | msn.comAnebulo Pharmaceuticals GAAP EPS of -$0.10 beats by $0.02November 14, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNovember 6, 2023 | finance.yahoo.comHere's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn SituationOctober 19, 2023 | msn.comAre Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?October 11, 2023 | benzinga.comDirector at Anebulo Pharmaceuticals Acquires Company Stock Options Worth 26,097 SharesOctober 6, 2023 | marketwatch.comAnebulo Pharmaceuticals Names Richie Cunningham as CEOOctober 6, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsOctober 6, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces New CEOSeptember 25, 2023 | msn.comHC Wainwright & Co. Reiterates Anebulo Pharmaceuticals (ANEB) Buy RecommendationSeptember 25, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)September 23, 2023 | nasdaq.comMaxim Group Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)September 20, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesSeptember 18, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 18, 2023 | markets.businessinsider.comSubstance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst SaysSeptember 18, 2023 | markets.businessinsider.comAnebulo Pharmaceuticals (ANEB) Has a New Rating from H.C. WainwrightAugust 30, 2023 | finance.yahoo.comAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesAugust 22, 2023 | finance.yahoo.comAnebulo (ANEB) Gains on Positive FDA Response for ANEB-001August 21, 2023 | markets.businessinsider.comAnebulo Pharma: FDA Provides Favorable Input On Studies To Support ANEB-001 ApprovalAugust 21, 2023 | finance.yahoo.comAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionMay 30, 2023 | finance.yahoo.comWe Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth CarefullyMay 19, 2023 | finance.yahoo.comDown -26.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Anebulo Pharmaceuticals, Inc. (ANEB)May 18, 2023 | msn.comBenchmark Reiterates Anebulo Pharmaceuticals (ANEB) Speculative Buy RecommendationMay 11, 2023 | finanznachrichten.deAnebulo Pharmaceuticals, Inc.: Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesMay 11, 2023 | msn.comAnebulo Pharmaceuticals: Q3 Earnings Insights Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address Top Stock Unveiled! (Ad)Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. Get Your Free Report ANEB Media Mentions By Week ANEB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANEB News Sentiment▼1.050.62▲Average Medical News Sentiment ANEB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANEB Articles This Week▼20▲ANEB Articles Average Week Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sol-Gel Technologies News OptiNose News ESSA Pharma News Aldeyra Therapeutics News Acrivon Therapeutics News Eliem Therapeutics News Prelude Therapeutics News 23andMe News Abeona Therapeutics News Shattuck Labs News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANEB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.